The Research Group on Molecular Therapies is made up of basic and clinical researchers from the Universitat de València, the La Fe University Hospital, the University Clinical Hospital of Valencia, the University Hospital of the Ribera, the National Cancer Research Centre and the Prince Felipe Research Centre.
The multidisciplinary composition of this group, which includes experts in molecular biology, bioinformatics and computational biology, medical oncology, surgery, pathology and new high-throughput technologies (genomics, transcriptomics, proteomics and metabolomics), allows the molecular complexity inherent to human diseases and the search for new therapies from an integrative and translational perspective. This approach is being applied in the different lines of research developed by the group, such as the identification of new biomarkers and molecular targets for the treatment of lung cancer, the physiopathology of pulmonary fibrosis, or the prevention and therapy of hypoxic-ischaemic neuropathies.
- New therapies directed against molecular targets in lung adenocarcinoma.
- New targeted therapies for pulmonary fibrosis.
- New therapies based on natural polyphenols.
- New therapies based on natural polyphenols
Identification of new markers associated with oxidative metabolism by mass spectrometry. Study of pathologies associated with oxidative stress and tissue hypoxia. Cellular and molecular mechanisms of the prevention of tissue damage in hypoxic-ischaemic neuropathies by means of natural and synthetic polyphenols.
- New targeted therapies in pulmonary fibrosis
Identification of new markers and molecular targets for the treatment of pulmonary fibrosis. Identification of molecular determinants of fibroblast-myofibroblast transition using omics technologies. Role of inflammation and stroma in the tumour microenvironment and lung cancer progression.
- New targeted therapies in lung cancer
Functional genomics of lung cancer. Identification of new markers and molecular targets for the treatment of lung cancer using omics technologies (transcriptomics, proteomics, metabolomics). Study of the mechanisms of innate and acquired resistance to tyrosine kinase inhibitors based on the epithelial-mesenchymal transition (EMT) and the cancer stem cell (CSC) phenotype. Regulation of tumour metabolism by oncogenes and suppressor genes in lung cancer.
- CARRETERO ASUNCION, JULIAN
- PDI-Titular d'Universitat
- ASENSI MIRALLES, MIGUEL ANGEL
- PDI-Catedratic/a d'Universitat
- PEREDA CERVERA, JAVIER
- Alumn.-Servei de Formacio Permanent
- Vicedega/Vicedegana / Vicedirector/a Ets
- CREMADES MIRA, ANTONIO
- PDI-Associat/Da Universitari/A
Contributors
- Fatima Al-Shahrour Núñez - National Cancer Research Centre (Madrid).
- Rosa Farrás Rivera - Prince Felipe Research Centre (Valencia).
- Óscar Juan Vidal - Institute for Health Research La Fe (Valencia).
- Agustín Lahoz Rodríguez - Institute for Health Research La Fe (Valencia).
- ExpandirPEREDA CERVERA, JAVIERAlumn.-Servei de Formacio PermanentVicedega/Vicedegana / Vicedirector/a Ets
Blasco Ibáñez Campus
Av. Blasco Ibáñez, 15
46010 València (Valencia)
- CARRETERO ASUNCION, JULIAN
- PDI-Titular d'Universitat
